Literature DB >> 25721897

Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.

N Shah1, P F Thall2, P S Fox2, Q Bashir1, J J Shah3, S Parmar1, P Lin4, P Kebriaei1, Y Nieto1, U R Popat1, C M Hosing1, A Cornelison1, E J Shpall1, R Z Orlowski3, R E Champlin1, M H Qazilbash1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25721897      PMCID： PMC4785590          DOI： 10.1038/leu.2015.54

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.

Authors:  Shaji K Kumar; Martha Q Lacy; Suzanne R Hayman; Keith Stewart; Francis K Buadi; Jacob Allred; Kristina Laumann; Philip R Greipp; John A Lust; Morie A Gertz; Steven R Zeldenrust; P Leif Bergsagel; Craig B Reeder; Thomas E Witzig; Rafael Fonseca; Stephen J Russell; Joseph R Mikhael; David Dingli; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

2.  Note on an exact treatment of contingency, goodness of fit and other problems of significance.

Authors:  G H FREEMAN; J H HALTON
Journal:  Biometrika       Date:  1951-06       Impact factor: 2.445

3.  Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma.

Authors:  Emilie Lemieux; Cyrille Hulin; Denis Caillot; Stéphanie Tardy; Véronique Dorvaux; Jessica Michel; Thomas Gastinne; Cédric Rossi; Caroline Legouge; Cyrille Touzeau; Lucie Planche; Marion Loirat; Ingrid Lafon; Philippe Moreau
Journal:  Biol Blood Marrow Transplant       Date:  2012-11-24       Impact factor: 5.742

4.  Durable remission with salvage second autotransplants in patients with multiple myeloma.

Authors:  Nina Shah; Fraz Ahmed; Qaiser Bashir; Sofia Qureshi; Yvonne Dinh; Gabriela Rondon; Sijin Wen; Peter Thall; Hassan Khan; Sergio Giralt; Richard Champlin; Muzaffar H Qazilbash
Journal:  Cancer       Date:  2011-11-15       Impact factor: 6.860

5.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

6.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Authors:  S K Kumar; J H Lee; J J Lahuerta; G Morgan; P G Richardson; J Crowley; J Haessler; J Feather; A Hoering; P Moreau; X LeLeu; C Hulin; S K Klein; P Sonneveld; D Siegel; J Bladé; H Goldschmidt; S Jagannath; J S Miguel; R Orlowski; A Palumbo; O Sezer; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2011-07-29       Impact factor: 11.528

7.  Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.

Authors:  Holger W Auner; Richard Szydlo; Alero Rone; Aristeidis Chaidos; Chrissy Giles; Ed Kanfer; Donald H Macdonald; David Marin; Dragana Milojkovic; Jiri Pavlu; Jane F Apperley; Amin Rahemtulla
Journal:  Leuk Lymphoma       Date:  2013-03-04

8.  Dose-finding based on efficacy-toxicity trade-offs.

Authors:  Peter F Thall; John D Cook
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

9.  Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.

Authors:  Niels W C J van de Donk; Shulamit Wittebol; Monique C Minnema; Henk M Lokhorst
Journal:  Br J Haematol       Date:  2010-01       Impact factor: 6.998

10.  Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.

Authors:  Nicole Wong Doo; Philip A Thompson; H Miles Prince; John F Seymour; David Ritchie; Kerrie Stokes; Kate Burbury; Max Wolf; Trish Joyce; Simon J Harrison
Journal:  Leuk Lymphoma       Date:  2012-12-14
View more
  6 in total

1.  Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Fabian Bock; Gary Lu; Samer A Srour; Sameh Gaballa; Heather Y Lin; Veerabhadran Baladandayuthapani; Medhavi Honhar; Maximilian Stich; Nina Das Shah; Qaiser Bashir; Krina Patel; Uday Popat; Chitra Hosing; Martin Korbling; Ruby Delgado; Gabriela Rondon; Jatin J Shah; Sheeba K Thomas; Elisabet E Manasanch; Berend Isermann; Robert Z Orlowski; Richard E Champlin; Muzaffar H Qazilbash
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-13       Impact factor: 5.742

2.  Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.

Authors:  Nina Shah; Li Li; Jessica McCarty; Indreshpal Kaur; Eric Yvon; Hila Shaim; Muharrem Muftuoglu; Enli Liu; Robert Z Orlowski; Laurence Cooper; Dean Lee; Simrit Parmar; Kai Cao; Catherine Sobieiski; Rima Saliba; Chitra Hosing; Sairah Ahmed; Yago Nieto; Qaiser Bashir; Krina Patel; Catherine Bollard; Muzaffar Qazilbash; Richard Champlin; Katy Rezvani; Elizabeth J Shpall
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

3.  High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.

Authors:  Yago Nieto; Benigno C Valdez; Sai R Pingali; Roland Bassett; Ruby Delgado; John Nguyen; Nina Shah; Uday Popat; Roy B Jones; Borje S Andersson; Alison Gulbis; Sairah Ahmed; Qaiser Bashir; Simrit Parmar; Krina Patel; Alan Myers; Gabriela Rondon; Robert Z Orlowski; Richard Champlin; Muzaffar Qazilbash
Journal:  Lancet Haematol       Date:  2017-05-15       Impact factor: 18.959

4.  CFO: Calibration-free odds design for phase I/II clinical trials.

Authors:  Huaqing Jin; Guosheng Yin
Journal:  Stat Methods Med Res       Date:  2022-03-03       Impact factor: 2.494

5.  Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells.

Authors:  E J Norris; D DeStephanis; B Tunquist; S Usmani; R Ganapathi; M Ganapathi
Journal:  Blood Cancer J       Date:  2016-10-07       Impact factor: 11.037

6.  Implementing the EffTox dose-finding design in the Matchpoint trial.

Authors:  Kristian Brock; Lucinda Billingham; Mhairi Copland; Shamyla Siddique; Mirjana Sirovica; Christina Yap
Journal:  BMC Med Res Methodol       Date:  2017-07-20       Impact factor: 4.615
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.